The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

2.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

3.

Are patients with advanced cancer receiving treatment aligned with their goals?

4.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

5.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot